Satellos Bioscience Inc.
MSCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 0.05 | 0.01 | -0.00 |
| FCF Yield | -25,651.52% | -39,053.30% | -68.96% | -20.45% |
| EV / EBITDA | 2,071.46 | 1,425.32 | -0.79 | -4.33 |
| Quality | ||||
| ROIC | -0.04% | -0.04% | -249.69% | -45.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.91 | 0.50 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -72.06% | -153.97% | -13.41% | -203.68% |
| Safety | ||||
| Net Debt / EBITDA | 2,074.96 | 1,427.73 | 0.24 | 1.07 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -4.81 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -55,262.97 | -43,053.19 | -1,588.41 | -2,694.72 |